文献速递头颈部肿瘤放疗放疗物理与技术

碳离子放疗头颈部腺样囊性癌的多中心研究:J-CROS 1402 HN亚组分析

Multicenter Study of Carbon-Ion Radiation Therapy for Adenoid Cystic Carcinoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-11-14

该多中心回顾性研究纳入2003年11月至2014年12月日本4家碳离子设施治疗的289例组织学证实头颈部腺样囊性癌患者,中位随访30个月,2年总生存率94%、无进展生存率68%、局部控制率88%,5年分别为74%、44%、68%,15%出现≥3级晚期毒性,2例鼻咽腺样囊性癌患者死于肿瘤部位出血性溃疡(5级毒性)。

要点

  • 头颈部腺样囊性癌碳离子放疗2年总生存率94%、局部控制率88%。
  • 5年总生存率74%、无进展生存率44%、局部控制率68%。
  • 15%患者出现≥3级晚期毒性,下颌骨坏死最常见;2例死于5级出血。

核心结论

  • 碳离子放疗似乎是头颈部腺样囊性癌有前景的治疗方式。

研究设计与样本

  • 回顾性分析日本4家碳离子设施2003年11月至2014年12月收治的289例组织学证实头颈部腺样囊性癌患者。
  • 中位年龄58岁(范围12-83岁),中位随访30个月(范围2-118个月)。

主要发现

  • 肿瘤部位:鼻腔及鼻旁窦42%、鼻咽及口咽19%、口腔12%、大唾液腺12%、其他15%。
  • T分期:T4 200例(69%)、T3 45例(16%)、T2 22例(8%)、T1 15例(5%)、未分类7例(2%)。
  • 中位总剂量64 Gy(RBE,范围55.2-70.4 Gy(RBE)),16次(范围12-32次)。
  • 2年总生存率94%、无进展生存率68%、局部控制率88%;5年总生存率74%、无进展生存率44%、局部控制率68%。
  • 43例(15%)出现≥3级晚期毒性,下颌骨坏死最常见;2例鼻咽腺样囊性癌患者死于肿瘤部位出血性溃疡(5级毒性)。

局限性

  • 本研究为回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To retrospectively analyze the treatment outcomes of carbon-ion radiation therapy for adenoid cystic carcinoma (ACC) of the head and neck at 4 active carbon-ion facilities in Japan. METHODS AND MATERIALS: A total of 289 patients who underwent carbon-ion radiation therapy for histology-proven ACC of the head and neck at 4 institutions in Japan between November 2003 and December 2014 were included in this study. RESULTS: Median patient age was 58 years (range, 12-83 years). Tumor sites included the nasal cavity and paranasal sinuses (42%), nasopharynx and oropharynx (19%), oral cavity (12%), major salivary glands (12%), and others (15%). Tumor classifications were T4 in 200 (69%) patients, T3 in 45 (16%), T2 in 22 (8%), T1 in 15 (5%), and unclassified in 7 (2%). The median total dose was 64 Gy (relative biological effectiveness [RBE]; range, 55.2-70.4 Gy [RBE]) in 16 fractions (range, 12-32 fractions). Median follow-up time was 30 months (range, 2-118 months). The 2-year overall survival, progression-free survival, and local control rates were 94%, 68%, and 88%, respectively. Estimated 5-year overall survival, progression-free survival, and local control rates were 74%, 44%, and 68%, respectively. In all, 43 patients (15%) experienced grade ≥3 late toxicity, of which osteonecrosis of the jaw bone was the most common. Two patients treated for nasopharyngeal ACC died from a bleeding ulcer at the tumor site (grade 5 toxicity). CONCLUSIONS: Carbon-ion radiation therapy seems to be a promising treatment for ACC of the head and neck.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sulaiman NS, Demizu Y, Koto M, et al. Multicenter Study of Carbon-Ion Radiation Therapy for Adenoid Cystic Carcinoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys. 2017. PMID: 29413278. doi:10.1016/j.ijrobp.2017.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。